Welcome back from Thanksgiving holiday! Can’t believe it’s already December…
This will be the only Impactiviti Daily this week, as I am heading down to South Carolina for the graduation of my #2 son (David) from Marine boot camp.
TODAY’S NEWS
Layoffs. Sanofi reps are apparently getting the news this week. Ugh.
Will Celgene‘s Revlimid take off even faster? – Celgene Corp. can more than triple sales for its best-selling cancer pill Revlimid on new data that may convince doctors to choose the drug as a first option over Johnson & Johnson’s intravenous medicine, Velcade.
Court to Glaxo reps seeking overtime pay: No. FDA to Novartis on seasonal flu shot: Yes.
RECOMMENDED
Speaker Training. The Impactiviti network of providers has what you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
Mystic the Marketing Lab gives her first interview. On canine branding.
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Connect with Steve Woodruff
